アレルギーと神経ペプチド　Vol.3　2007年

出版社： 日本医学館
著者：
発行日： 2007-02-15
分野： 臨床医学：内科  >  アレルギー
ISBN： 9784890440030
電子書籍版： 2007-02-15
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

1,100 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

550 円(税込)

購入する

商品紹介

本特集は、第3回アレルギーと神経ペプチド編集会議（2006年11月）での内容をその後おのおの執筆してまとめたものである。

目次

  • アレルギーと神経ペプチド　Vol.3　2007年

    ―目次―

    ＴＲＰチャンネルと気道過敏性

    特集　“気道におけるバニロイド受容体と神経ペプチド”

    PRESENTATION 　　
    ●気道におけるバニロイド受容体に対する免疫組織化学的
    　　アプローチ − 神経ペプチドとの関係を含めて

    COMMENT & IMPRESSION 　　
    ●気道におけるバニロイド受容体の役割と神経ペプチドとの関係
    ●TRPV1刺激による神経ペプチド遊離の新たな可能性
    ●皮膚のアレルギー炎症とバニロイド受容体
    ●TRPV1受容体の気道における分布とその役割
    ●皮膚アレルギーとバニロイド受容体
    ●アレルギー性鼻炎とバニロイド受容体
    ●下気道の神経原性炎症におけるバニロイド受容体の役割

    REVIEW & TOPICS
    ●アレルギー性鼻炎と神経ペプチド
    ●皮膚神経系からみた免疫調整外用薬タクロリムス軟膏の止痒機序
    ●VIPの気道における役割とその意義
    ●ケラチノサイトおよび血管内皮細胞の炎症性分子発現に対する
    　　塩酸オロパタジンの抑制効果 　　

    EDUCATIONAL LECTURE
    ●アレルギー性鼻炎モデルからみた鼻過敏症の意義 　　
    ●アレルギーと肥満細胞 ― 古くて新しいテーマの検証

    DRUG-REPORT
    ●Nueropeptide Y受容体を標的にした創薬の可能性

    文献紹介
    1． ブラジキニンはアトピー性皮膚炎での痒み惹起因子である：
    　　　痛みから痒みへのスイッチ（Hosogi M et al.）
    2． アレルギー性炎症では気道上皮細胞がニューロトロフィンを
    　　　産生し，好酸球の生存を延長する（Hahn C et al.）
    3． ニューロメディンＵは好酸球を活性化し，アレルゲン誘発性
    　　　好酸球増多症に関わっている（Moriyama M et al.）

    WAVE OF MEDICINE
    ●“ニューロペプタイド研究会のあゆみ”第14回研究会報告

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特集 "気道におけるバニロイド受容体と神経ペプチド"

P.10 掲載の参考文献
1) Horie S, Yamamoto H, Michael GJ, Uchida M. Belai A, Watanabe K, Priestley JV, Murayama T:Protetive role of Vanilloid receptor type 1 in HCI-induced gatric mucosal lesion in rats. Tylor & Francis 2004, 4:303-312.
 
2) Seki N, Shirasaki H, Kikuchi M, Sakamoto T, Watanabe N, Himi T:Expression and localization of TRPV 1 in human nasal mucosa. Rhinology 2006, 44:128-134.
 
3) 富永真琴:知覚神経・TRPV1の構造と機能を探る. G. I. Research 2005, 13:339-345.
Medical*Online
4) 渡邉直人, Spina D, 堀江俊治, 牧野荘平, 福田 健, Priestley JV, Page CP:節上神経におけるバニロイド受容体(VR1)の分布状況とCGRP, substance Pとの関係. アレルギー 2005, 54:385.
 
5) Watanabe N, Horie S, Michel GJ, Spina D, Page CP, Priestley JV:Immunohistochemical localization of vanilloid receptor subtype 1 in the guinea pig respiratory system. Pulmonary Pharmacology &Therapeutics 2005, 18:187-197.
 
6) Watanabe N, Horie S. Michael GJ, Keir S, Spina D, Page CP, Priestley JV:Immunohistochemical co-localization of transient receptor potential vanilloid (TRPV) 1 and sensory neuropeptides in the guinea-pig respiratory system. Neuroscience 2006, 141:1533-1543.
PubMed
7) Forsberg K, Karlsson JA, Theodorsson E, Lundberg JM, Persson CG:Cough and bronchoconstriction mediated by capsaicin-sensitive sensory neurons in the guinea-pig. Pulm Pharmacol 1988, 1:33-39.
PubMed
8) Tucker RC, Kagaya M, Page CP, Spina D:The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways. Br J Pharmacol 2001, 132:1127-1135.
PubMed
P.13 掲載の参考文献
1) Groneberg DA et al:Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med 2004, 170:1276-1280.
PubMed
2) Barnes PJ:Asthma as an axon reflex. Lancet 1986, 11242-245.
 
3) Moriyama M et al:The neuropeptide neuromedin U activates eosinophils abd is involved in allergen-induced eosinophilia. Am J Physiol Lung Cell Mol Physiol 2006, 290:L971-L977.
 
P.16 掲載の参考文献
1) Caterina MJ et al.:Nature 1997, 389:816-824.
PubMed
2) Inoue K et al.:Biochem Biophys Res Commun 2002, 291:124-912.
PubMed
3) Southall MD et al.:J Pharmacol Exp Ther 2003. 304:217-222.
PubMed
4) Tatemoto T et al.:Biochem Biophys Res Commun 2006, 349:1322-1328.
 
5) van der Kleij HP et al.:J Immunol 2003, 171:2074-2079.
PubMed
P.18 掲載の参考文献
1) Yoshihara S, Morimoto H, Yamada Y, Abe T, Arisaka O:Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea-pig airway. Int Arch Allergy Immunol 2005, 138:80-87.
PubMed

REVIEW & TOPICS

P.21 掲載の参考文献
1) Barnes PJ:Asthma as an axon reflex. Lancet 1986, 1:242-245.
PubMed
2) Baraniuk JN, Ohkubo K, Kwon OJ, Mak J, Rohde J et al.:Identification of neutral endopeptidase mRNA in human nasal mucosa. J Appl Physiol 1993, 74:272-279.
PubMed
3) Ohkubo K, Okuda M, Kaliner MA:Immunological localization of neuropeptide-degrading enzymes in the nasal mucosa. Rhinology 1994, 32:130-133.
PubMed
4) Ohkubo K, Baraniuk JN, Merida M, Hausfeld JN, Okada H, Kaliner MA:Human nasal mucosal carboxypeptidase:activity, location, and release. J AIIergy Clin Immunol 1995, 96:924-931.
PubMed
5) Tonnesen P, Hindberg I, Schaffalitzky de Muckadell OB, Mygind N:Effect of nasal allergen challenge on serotonin, substance P and vasoactive intestinal peptide in plasma and nasal secretions. Allergy 1988, 43:310-317.
PubMed
6) Mosimann BL, White MV, Hohman RJ, Goldrich MS, Kaulbach HC, Kaliner MA:Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. J AIIergy Clin Immunol 1993, 92:95-104.
PubMed
7) Okamoto Y, Shirotori K, Kudo K, Ishikawa K, Ito E et al.:Cytokine expression after the topical administration of substance P to human nasal mucosa. The role of substance P in nasal allergy. J Immunol 1993, 151:4391-4398.
PubMed
8) 後藤 穣:ブラディキニン鼻誘発反応におけるアンギオテンシン変換酵素の関与 正常者と鼻アレルギー症例の比較. 日本耳鼻咽喉科学会会報 1999, 102:218-225.
Medical*Online
9) Sarin S, Undem B, Sanico A, Togias A:The role of the nervous system in rhinitis. J Allergy Clin Immunol 2006, 118:999-1014.
PubMed
10) Turner P, Dear J, Scadding G, Foreman JC:Role of kinins in seasonal allergic rhinitis:Icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J AIIergy Clin Immunol 2001, 107:105-113.
PubMed
11) Cortes L, Carvalho AL, Todo-Bom A, Faro C, Pires E, Verissimo P:Purification of a novel aminopeptidase from the pollen of Parietaria judaica that alters epithelial integrity and degrades neuropeptides. J Allergy Clin Immunol 2006, 118:878-884.
PubMed
P.26 掲載の参考文献
1) 今山修平:アトピー性皮膚炎の痒みup date-患者では表皮内神経線維が不規則に増加-. MB Derma 2005, 104:43-47.
 
2) Pincelli C, Marconi A:Autocrine nerve growth factor in human keratinocytes. J Dermatol Sci 2000, 22:71-79.
PubMed
3) 豊田雅彦, 諸橋正昭:皮膚アレルギーと痒み. アレルギー科 2001, 12:600-608.
 
4) Andoh T, Nagasawa T, Satoh M, Kuraishi Y:Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 1998, 286:1140-1145.
PubMed
5) Kuraishi Y, Nagasawa T, Hayashi K, Satoh M:Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmaco1 1995, 275:229-233.
 
6) Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC:Neuropeptides in the skin:interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998, 7:81-96.
PubMed
7) 田村遵一・他:シクロスポリン A と FK506 の免疫抑制の分子機構. 標的酵素カルシニューリンを中心に. 実験医学 1993, 11:791-797.
 
8) Stander S, Luger TA:Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt 2003, 54:413-417.
PubMed
9) Katoh N, Hirano S, Yasuno H, Kishimoto S:Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis. J Dermatol 2004, 31:194-199.
PubMed
10) Inagaki N, Shiraishi N, Igeta K, Itoh T, Chikumoto T et al:Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not by dexamethasone. Eur J Pharmacol 2006, 546:189-196.
PubMed
11) 豊田雅彦:アトピー性皮膚炎:止痒剤としてのタクロリムス. MB Derma 2005, 101:15-24.
 
P.29 掲載の参考文献
1) Said SI. Mutt V:Polypeptide with broad biological activity:isolation from small intestine. Science 1970, 169:1217-1218.
PubMed
2) Laitinen A, Partanen M, Hervonen A et al.:VIP like immunoreactive nerves in human respiratory tract. Light and electron microscopic study. Histochemistry 1985, 82:313-319.
PubMed
3) Ghatei MA, Sheppard MN, O'Shaughnessy DJ et al.:Regulatory peptides in the mammalian respiratory tract. Endocrinology 1982, 111:1248-1254.
 
4) Lundberg JM, Fahrenkrug J, Hokfelt T et al:Co-existence of peptide HI(PHI)and VIP in nerves regulating blood flow and bronchial smooth muscle tone in various mammals including man. Peptides 1984, 5:593-606.
PubMed
5) Said SI:Vasoactive peptides in the lung, with special reference to vasoactive intestinal peptide. Exp Lung Res 1982, 3:343-348.
PubMed
6) Berisha HI, Bratut M, Bangale Y et al:New evidence for transmitter role of VIP in the airways:impaired relaxation by a catalytic antibody. Pul Pharmacol Ther 2002, 15:121-127.
 
7) Linder S, Barkhem T, Norberg A et al.:Structure and expression of the gene encoding the vasoactive intestinal peptide precursor. Proc Natl Acad Sci USA 1987, 84:605-609.
PubMed
8) Goetzl EJ, Sreedharan SP, Turck CW et al.:Preferential cleavage of amino-and carboxyl-terminal oligopeptides from vasoactive intestinal polypeptide by human recombinant enkephalinase(neutral endopeptidase, EC 3. 4. 24. 11). Biochem Biophys Res Commun 1989, 158:850-854.
PubMed
9) Caughey GH, Leidig F, Viro NF et al.:Substance P and vasoactive intestinal peptide degradalion by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988, 244:133-137.
PubMed
10) Ishihara T, Shigemoto R, Mori K et al.:Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992, 8:811-819.
PubMed
11) Groneberg DA, Hartmann P, Dinh QT et al:Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways. Lab Invest 2001, 81:749-755.
PubMed
12) Ganz P, Sandrock AW, Landis SC et al.:Vasoactive intestinal peptide:vasodilatation and cyclic AMP generation. Am J Physiol 1986, 250:H755-H760.
PubMed
13) Fischer A, Folkerts G, Geppetti P et al.:Mediators of asthma:nitric oxide. Pulm Pharmacol Ther 2002, 15:73-81.
PubMed
14) Eynott PR, Groneberg DA, Caramori G et al:Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness. Eur J Pharmacol 2002, 452:123-133.
PubMed
15) Matsuzaki Y, Hamasaki Y, Said SI:Vasoactive intestinal peptide:a possible transmitter of nonadrenergic relaxation of guinea pig airways. Science 1980, 210:1252-1253.
PubMed
16) Moncada S, Palmer RM, Higgs EA:Nitric oxide;physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-134.
PubMed
17) Belvisi M, Stretton D, Verleden GM et al.:Nitric Oxide is the endogenous transmitter of bronchodilator nerves in humans. Eur J Pharmacol 1992, 210:221-222.
 
18) Grider JR, Murthy KS, Jin JG et al.:Stimulation of nitric oxide from muscle cells by VIP:prejunctional enhancement of VIP release. Am J Physiol 1992, 262:G774-G778.
PubMed
19) Hasaneen NA, Foda HD, HD. Said SI:Nitric oxide and vasoactive intestinal peptide as co-transminers of airway smooth-muscle relaxation;analysis in neuronal nitric oxide synthase knockout mice. Chest 2003, 124:1067-1072.
 
20) Said SI:Nitric oxide and vasoactive intestinal peptide as cotransmitter of smooth muscle relaxation. News Physiol Sci 1992, 7:181-183.
 
21) Groneberg DA, Springer J, Fischer A:Vasoactive intestinal polypeptide as mediator of asthma. Pulm Pharmacol Ther 2001, 14:391-401.
PubMed
22) Hamasaki Y, Saga T, Mojarad M et al.:Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery. Trans Assoc Am Physicians 1983, 96:406-411.
PubMed
23) Saga T, Said SI:Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984, 97:304-310.
PubMed
24) Peatfield AC, Barnes PJ, Bratcher C et al:Vasoactive intestinal peptide stimulates tracheal submucosal gland secretion in ferret. Am Rev Respir Dis 1983, 128:89-93.
PubMed
25) Webber SE, Widdicombe JG:The effect of vasoactive lntestinal peptide on smooth muscle tone and mucus secretion from the ferret trachea. Br J Pharmacol 1987, 91:139-148.
 
26) Voice JK, Dorsam G, Lee H, Kong Y et al.:Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J 2001, 15:2489-2496.
PubMed
27) Diamond L, Szarek JL, Gillespie MN et al.:In vivo bronchodilator activity of vasoactive intestinal peptide in the cat. Am Rev Respir Dis 1983, 128:827-832.
PubMed
28) Barnes PJ, Dixon CM:The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis 1984, 130:162-166.
PubMed
29) Kallstrom B-L, Waldeck B:Bronchodilating propaties of the VIP receptor agonist Ro 25-1553 compared to those of formoterol on the guinea-pig isolated trachea. Eur J Pharmacol 2001, 430:335-340.
PubMed
30) Groneberg DA:Novel concepts of neuropeptide-based drug therapy:Vasoactive intestinal polypeptide and its receptors Eur J Pharmacol 2006, 533:182-194.
PubMed
P.31 掲載の参考文献
1) Ohmori K, Hasegawa K, Tamura T et al.:Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung 2004, 54:809-829.
PubMed
2) Kanda N, Watanabe S:Histamine enhances the production of granulocyte-macrophage colony-stimulating factor via protein kinase Cα and extracellular signal-regulated kinase in human keratinocytes. J Invest Dermatol 2004, 122:863-872.
 
3) Kohda F, Koga T, Uchi H et al.:Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-γ and IL-4 in human keratinocytes. J Dermatol Sci 2002, 28:34-41
 
4) Kanda N, Watanabe S:Histamine enhances the production of nerve growth factor in human keratinocytes. J Invest Dermatol 2003, 121:570-577.
PubMed
5) Matsubara M, Tamura T, Ohmori K et al.:Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/IκB/NF-κB signal cascades. Biochem Pharmacol 2005, 69:433-449.
 
6) Raychaudhuri SK, Raychaudhuri SP, Weltman H et al.:Effect of nerve growth factor on endothelial cell biology:proliferation and adherence molecular expression on human dermal micorvascular endothelial cells. Arch Dermatol Res 2001, 293:291-295.
 
7) Quinlan KL, Song IS, Bunnett NW et al.:Neuropeptide regulation of human dermal micorvascular endothelial cell ICAM-1 expression and function. Am J Physiol 1998, 275:C1580-C1590.
 
8) Miki I, Kusano A, Ohta S et al.:Histamine enhanced the TNFα-induced expression of E-selectin and ICAM-1 on vascular endothelial cells. Cellular Immunol 1996, 171:285-288.
 
9) Tamura T, Amano T, Ohmori K et al.:The effects of olopatadine hydrochloride on the number of scratching induced by repeated application of oxazolone in mice. Eur J Pharmaco12005, 524:149-154.
PubMed

EDUCATIONAL LECTURE

P.38 掲載の参考文献
1) Nabe T, Shimizu K, Mizutani N, Saeki Y, Yamamura H et al.:A new model of experimental allergic rhinitis using Japanese cedar pollen in guinea pigs. Jpn J Pharmacol 1997, 75:243-251.
PubMed
2) Nabe T, Mizutani N, Shimizu K, Takenaka H, Kohno S:Development of pollen-induced rhinitis with early and late phase nasal blockage in guinea pigs. Inflamm Res 1998, 47:369-374.
PubMed
3) Mizutani N, Nabe T, Sasaki K, Takenaka H, Kohno S:Nasal hyperresponsiveness to histamine induced by repetitive exposures to cedar pollen in guinea pigs. Eur Respir J 1999, 14:1368-1375.
 
4) Mizutani N, Nabe T, Imai A, Sakurai H, Takenaka H et al: Markedly increased nasal blockage by intranasal leukotriene D4 in an experimental allergic rhinitis model:contribution of dilated mucosal blood vessels. Jpn J Phammacol 2001, 86:170-182.
 
5) Mizutani N, Nabe T, Takenaka H, Kohno S:Acquired nasal hyperresponsiveness aggravates antigen-induced rhinitis in the guinea pig. J Pharmacol Sci 2003, 93:437-445.
PubMed
6) Pennock BE, Cox CP, Rogers RM, Cain WA, Wells JH:A noninvasive technique for measurement of changes in specific airway resistance. J Appl Physiol 1979, 46:399-406.
PubMed
7) Narita S, Asakura K, Kataura A:effects of thromboxane A2 receptor antagonist(Bay u 3405)on nasal symptoms after antigen challenge in sensitized guinea pigs. Int Arch Allergy Immunol 1996, 109:161-166.
PubMed
8) Narita S, Asakura K, Shirasaki H, Kataura A:Effects of a cysteinyl leukotriene antagonist, ONO-1078(pranlukast), on total airway resistance after antigen challenge in sensitized guinea pigs. Inflamm Res 1997, 46:143-146.
PubMed
9) Konno A, Togawa K, Nishihira S:Seasonal variation of sensitivity of nasal mucosa in pollinosis. Arch Otorhinolaryngol 1981, 232:253-261.
PubMed
10) Kanthawwatana S, Maturim W, Fooanant S, Manorol M, Trakultivakorn M:Evaluation of threshold criteria for the nasal histamine challenge test in perennial allergic rhinitis. Asian Pac J Allergy Immunol 1997, 15:65-69.
 
11) amasaki M, Mizutani N, Sasaki K, Nabe T, Matsumoto T et al.:Involvement of thromboxane A2 and peptide leukotrienes in early and late phase nasal blockage in a guinea pig model of allergic rhinitis. Inflamm Res 2001, 50:466-473.
 
12) Donnelly AL, Glass M, Minkwitz MC, Casale TB:The leukotriene D4-receptor antagonist, ICI 204, 219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Cri Care Med 1995, 151:1734-1739.
 
13) Christiansen SC, Eddleston J, Woessner KM, Chambers SS, Ye R et al.:Up-regulation of functional kinin B, receptors in allergic airway inflammation. J Immunol 2002, 169:2054-2060.
 
14) Sugahara S, Nabe T, Mizutani N, Takenaka H, Kohno S:Kinins are involved in the development of allergic nasal hyperresponsiveness in guinea pigs. Eur J Pharmacol 2003, 476:229-237.
PubMed
15) Turner P, Dear J, Scadding G, Foreman JC:Role of kinins in seasonal allergic rhinitis:icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. J Allergy Clin Immunol 2001, 107:105-113.
PubMed
16) Proud D, Siekierski ES, Bailey GS:Identification of human lung mast cell kininogenase as tryptase and relevance of tryptase kininogenase activity. Biochem Phamacol 1988, 37:1473-1480.
 
17) Walls AF, Bennett AR, Sueiras-Diaz J, Olsson H:The kininogenase activity of human mast cell tryptase. Biochem Soc Trans 1992, 20:260S,
 
18) Imamura T, Dubin A, Moore W, Tanaka R, Travis J:Induction of vascular permeability enhancement by human tryptase:dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab Invest 1996, 74:861-870.
PubMed
19) 大谷泰功, 水谷暢明, 藤井正徳, 奈邉 健, 河野茂勝:実験的アレルギー性鼻炎のくしゃみ, 鼻閉および鼻過敏症の発症におけるNK1およびNK2受容体の役割について. アレルギー 2006, 55:1126.
Medical*Online
P.42 掲載の参考文献
1) Rivera J:Molecular adapters in FcεRI signaling and the allergic response. Curr Opin Immunol 2002, 14:688-693.
 
2) Metcalfe DD, Baram D, Mekori YA:Mast cells. Physiol Rev 1997, 77:1033-1079.
PubMed
3) Fukuishi N, Metcalfe DD, Kulka M:Sounding the alarm in infection:mast cells counter-attack. Journal of the World Allergy Organization 2004, 16:70-74.
 
4) Varadaradjalou S, Feger F, Thieblemont N, Hamouda NB, Pleau JM et al.:Toll-like receptor 2(TLR2)and TLR4 differentially activate human mast cells. Eur J Immunol 2003, 33:899-906.
PubMed
5) Malaviya R, Gao Z, Thankavel K, van der Merwe PA, Abraham SN:The mast cell tumor necrosis factor a response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc Natl Acad Sci USA 1999, 96:8110-8115.
PubMed
6) Flohr C, Pascoe D, Williams HC:Atopic dermatitis and the 'hygiene hypothesis':too clean to be true? Br J Dermatol 2005, 152:202-216.
PubMed
7) Hickman SP, Chan J, Salgame P:Mycobacterium tuberculosis induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization, J Immunol 2002, 168:4636-4642.
PubMed
8) Zheng W, Flavell RA:The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587-596.
 
9) Schaller M, Hogaboam CM, Lukacs N, Kunkel SL:Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response. J Allergy Clin Immunol 2006, 118:295-302.
PubMed
10) Hodge D, Chetcuti PA:RSV:Management of the acute episode. Paediatr Respir Rev 2000, 1:215-220.
PubMed
11) Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S et al:Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005, 171:137-141.
PubMed
12) Pala P, Bjarnason R, Sigurbergsson F, Metcalfe C, Sigurs N, Openshaw PJ:Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. Eur Respir J 2002, 20:376-382.
PubMed
13) Lemanske RF Jr, Dick EC, Swenson CA, Vrtis RF, Busse WW:Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J CIin Invest 1989, 83:1-10.
 
14) Grunberg K, Timmers MC, Smits HH, de Klerk EP, Dick EC et al.:Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp AHergy 1997, 27:36-45.
PubMed
15) Kulka M, Fukuishi N, Rottem M, Mekori YA, Metcalfe DD:Mast cells, which interact with Escherichia coli, up-regulate genes associated with innate immunity and become less responsive to FcεRI-mediated activation. J Leukoc Biol 2006, 79:339-350.
 
16) Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M et al.:Allergy and endotoxin study team:environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002, 347:869-877.
 
17) Velasco G, Campo M, Manrique OJ, Bellou A, He H et al:Toll- like receptor 4 or 2 agonists decrease allergic inflammation. Am J Respir Cell Mol Biol 2005, 32:218-224.
PubMed
18) Zasloff M:Magainins, a class of antimicrobial peptides from Xenopus skin:isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA 1987, 84:5449-5453.
PubMed
19) Jacob L, Zasloff M:Potential therapeutic applications of magainins and other antimicrobial agents of animal origin. Ciba Found Symp 1994, 186:197-216.
PubMed
20) Fukuishi N, Yoshioka M, Akagi M:The role of mast cells in allergic inflammation-from the view point of innate immune system involvement. Nippon Yakurigaku Zasshi 2005, 125:259-264.
PubMed
21) Harder J, Bartels J, Christophers E, Schroder JM:Apeptide antibiotic from human skin. Nature 1997, 387:861.
 
22) Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I:Evaluation of the effects of peptide antibiotics human B-defensins- 1/-2 and LL-37 on histamine release and prostaglandin D2 production from mast cells. Eur J Immunol 2001, 31:1066-1075.
 
23) Niyonsaba F, Iwabuchi K, Matsuda H, Ogawa H, Nagaoka I:Epithelial cell-derived human β-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int Immunol 2002, 14:421-426.
 
24) Niyonsaba F, Ushio H, Nagaoka I, Okumura K, Ogawa H:The human β-defensins(-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 2005, 175:1776-1784.
 
25) Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K et al:Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol advance online publication, 2006.
 
26) Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A et al.:Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 2002, 298:10255-10259.
 
27) Izadpanah A, Gallo RL:Antimicrobial peptides. J Am Acad Dermatol 2005, 52:381-390.
PubMed
28) Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M:Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001, 108:516-520.
 
29) Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T et al.:Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J AIIergy Clin Immunol 2003, 111:587-591.
PubMed
30) Guzik TJ, Bzowska M, Kasprowicz A, Czerniawska-Mysik G, Wojcik K et al.:Persistent skin colonization with Staphylococcus aureus in atopic dermatitis:relationship to clinical and immunological parameters. Clin Exp Allergy 2005, 35:448-455
 

DRUG-REPORT

P.44 掲載の参考文献
1) Reiche EM, Nunes SO, Morimoto HK:Stress, depression, the immune system, and cancer. Lancet Oncol 2004, 5:617-625.
PubMed
2) Prod'homme T, Weber MS, Steinman L, Zamvil SS:A neuropeptide in immune-mediated inflammation, Y? Trends Immunol 2006, 27:164-167.
 
3) Naveilhan P, Hassani H, Lucas G, Blakeman KH, Hao JX et al.:Reduced antinociception and plasma extravasation in mice lacking aneuropeptide Y receptor. Nature 2001, 409:513-517.
PubMed
P.45 掲載の参考文献
4) Kawamura N, Tamura H, Obana S, Wenner M, Ishikawa T et al.:Differential effects of neuropeptides on cytokine production by mouse helper T cell subsets. Neuroimmunomodulation 1998, 5:9-15.
PubMed
5) Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D et al.:A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med 2005, 202:1527-1538.
PubMed
6) Bedoui S, Miyake S, Lin Y, Miyamoto K, Old S et al.:Neuropeptide Y(NPY) suppresses experimental autoimmune encephalomyelitis:NPY1 receptor-specific inhibition of autoreactive Th l responses in vivo. J Immunol 2003, 171:3451-3458.
 
7) Hassani H, Lucas G, Rozell B, Ernfors P:Attenuation of acute experimental colitis by preventing NPY Y1 receptor signaling. Am J Physiol Gastrointest Liver Physiol 2005, 288:G550-G556.
PubMed
8) Groneberg DA, Folkerts G, Peiser C, Chung KF, Fischer A:Neuropeptide Y(NPY). Pulm Pharmacol Ther 2004, 17:173-180
 
9) Cervin A, Onnerfalt J, Edvinsson L, Grundemar L:Functional effects of neuropeptide Y receptors on blood flow and nitric oxide levels in the human nose. Am J Respir Crit Care Med 1999, 160:1724-1728.
PubMed
10) Lacroix JS, Mosimann BL:Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients. J Allergy Clin Immunol 1996, 98:611-616.
PubMed
11) Lacroix JS, Ricchetti AP, Morel D, Mossimann B, Waeber B Grouzmann E:intranasal administration of neuropeptide Y in man:systemic absorption and functional effects. Br J Pharmacol 1996, 118:2079-2084.
PubMed

書評

最近チェックした商品履歴

Loading...